Kreicbergs A, Boquist L, Borssén B, Larsson S E
Cancer. 1982 Aug 1;50(3):577-83. doi: 10.1002/1097-0142(19820801)50:3<577::aid-cncr2820500332>3.0.co;2-g.
In a retrospective study of 45 surgically treated chondrosarcomas, the prognostic significance of the cellular DNA content and different clinicopathologic factors was analyzed with separately and in combination. The relationship between these parameters was also investigated. Diploid (normal DNA content) chondrosarcomas were associated with as significantly (P less than 0.001) higher ten-year survival rate than hyperploid (abnormally increased DNA content) chondrosarcomas. Apart from ploidy, factors such as tumor size, tumor location and tumor grade also proved to be of prognostic importance. However, patients with diploid tumors had a better prognosis than those with hyperploid tumors, almost regardless of location, size, grade or even treatment. Nevertheless, additional prognostic information could be obtained by combining ploidy with size, location and grade of the tumors. Ploidy and treatment were significantly related to the ten-year recurrence rate. No statistical relationship could be demonstrated between ploidy and other prognostic factors. A strong correlation (P less than 0.001) was, however, found between location and size of the tumors. Thus, distal tumors were significantly smaller and, moreover associated with a better prognosis than axial tumors. The results indicate that ploidy probably is the best predictor of the clinical course in chondrosarcoma. While tumor location and size may be assumed to determine the conditions for radical surgery, ploidy and grade seem to reflect the inherent biological malignancy in chondrosarcoma. Consideration of these factors seems to provide not only valuable prognostic information, but also guidelines for treatment.
在一项对45例接受手术治疗的软骨肉瘤的回顾性研究中，分别并综合分析了细胞DNA含量及不同临床病理因素的预后意义。还研究了这些参数之间的关系。二倍体（正常DNA含量）软骨肉瘤的十年生存率显著高于超二倍体（DNA含量异常增加）软骨肉瘤（P<0.001）。除了倍性外，肿瘤大小、肿瘤位置和肿瘤分级等因素也被证明具有预后意义。然而，几乎无论肿瘤位置、大小、分级甚至治疗情况如何，二倍体肿瘤患者的预后均优于超二倍体肿瘤患者。尽管如此，将倍性与肿瘤大小、位置和分级相结合可获得更多的预后信息。倍性和治疗与十年复发率显著相关。倍性与其他预后因素之间未显示出统计学关系。然而，肿瘤位置和大小之间存在强相关性（P<0.001）。因此，远端肿瘤明显较小，而且与轴向肿瘤相比预后更好。结果表明，倍性可能是软骨肉瘤临床病程的最佳预测指标。虽然肿瘤位置和大小可能决定根治性手术的条件，但倍性和分级似乎反映了软骨肉瘤内在的生物学恶性程度。考虑这些因素似乎不仅能提供有价值的预后信息，还能为治疗提供指导。
